Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children
about
Lack of artemisinin resistance in Plasmodium falciparum in northwest Benin after 10 years of use of artemisinin-based combination therapyArtemisinin Action and Resistance in Plasmodium falciparumPlasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia.High throughput resistance profiling of Plasmodium falciparum infections based on custom dual indexing and Illumina next generation sequencing-technology.Reply to Plucinski et al., "Interpreting Data from Passive Surveillance of Antimalarial Treatment Failures".Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Ugandapfk13-Independent Treatment Failure in Four Imported Cases of Plasmodium falciparum Malaria Treated with Artemether-Lumefantrine in the United Kingdom.Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence.Impacts of Antimalarial Drugs on Plasmodium falciparum Drug Resistance Markers, Western Kenya, 2003-2015.Polymorphisms in the K13 Gene in Plasmodium falciparum from Different Malaria Transmission Areas of Kenya.Prevalence of antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014No polymorphisms in K13-propeller gene associated with artemisinin resistance in Plasmodium falciparum isolated from Brazzaville, Republic of CongoA single nucleotide polymorphism in the Plasmodium falciparum atg18 gene associates with artemisinin resistance and confers enhanced parasite survival under nutrient deprivation
P2860
Q26209187-9929195D-B581-4DE0-8D83-0982D088C6B4Q28276294-2BEE7939-5785-4803-A44B-3B47953D845EQ30240158-247869E0-F55F-4BDA-A88D-970DDD3AEF69Q33729200-9F876DFD-3B0F-4C6E-97C0-F3905E6D5128Q36379439-15ECE6B8-39E0-4464-94D9-48DB31D26443Q37576425-F9E2AA7A-D898-4E1A-9337-CA02F7FBE98CQ37669829-A1B34750-573D-4D75-A75E-594A8925EA81Q43923927-F5AD58E1-8B7E-4F8B-9BC8-F342372E30F6Q48023089-3B80053E-9AE9-417B-AD49-ABC9FBB60528Q51144485-3E02B5AC-2115-4004-8B9A-B16D53D49A9BQ57945219-00FC65C3-91DD-4355-A3C3-255231755F3BQ58101228-A7D1143A-8128-4B8A-A506-4A08C5B1634FQ58115287-A56F2698-C410-412D-8C87-42A2D53A800D
P2860
Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Lack of K13 mutations in Plasm ...... y treatment of Kenyan children
@ast
Lack of K13 mutations in Plasm ...... y treatment of Kenyan children
@en
type
label
Lack of K13 mutations in Plasm ...... y treatment of Kenyan children
@ast
Lack of K13 mutations in Plasm ...... y treatment of Kenyan children
@en
prefLabel
Lack of K13 mutations in Plasm ...... y treatment of Kenyan children
@ast
Lack of K13 mutations in Plasm ...... y treatment of Kenyan children
@en
P2093
P2860
P50
P921
P1433
P1476
Lack of K13 mutations in Plasm ...... y treatment of Kenyan children
@en
P2093
Gisela Henriques
Julian Muwanguzi
Patrick Sawa
P2860
P2888
P356
10.1186/S12936-016-1095-Y
P577
2016-01-22T00:00:00Z
P5875
P6179
1028832977